IP Library Granted Patent US 8,945,602
Granted Patent B2
US 8,945,602 · App. 13/854,039 · Granted Feb 3, 2015

Porous photonic crystals for drug delivery to the eye

Inventors: William Freeman (Del Mar, CA); Michael J. Sailor (La Jolla, CA); Lingyun Cheng (San Diego, CA); Frederique Cunin (Montpellier, FR); Emily Anglin (San Diego, CA); Yang Yang Li (Hong Kong, HK)
Assignee: The Regents of the University of California
A61K9/0048A61F9/0017A61K9/0051A61K47/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,945,602
App. No.
13/854,039
Granted
Feb 3, 2015
Kind
B2
Abstract

A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.

Claims (11)

1. A method for treating an intraocular disease of the eye comprising administering to an eye of a patient a porous silicon dioxide particle having pores comprising a drug for treatment of the disease, thereby delivering the drug to the eye.

2. The method of claim 1 , wherein the porous silicon dioxide particle has a dimension of from 1 μm to 270 μm.

3. The method of claim 1 , wherein the porous silicon dioxide particle has a dimension of from 10 μm to 45 μm.

4. The method of claim 1 , wherein the porous silicon dioxide particle has a free volume of from 50% to 80% based on the total volume of the porous silicon dioxide particle.

5. The method of claim 1 , wherein the administering comprises injection.

6. The method of claim 5 , wherein the administering comprises intravitreal injection.

7. The method of claim 1 , wherein the drug is a protein or peptide.

8. The method of claim 7 , wherein the protein or peptide is selected from the group consisting of pigment epithelium derived factor (PEDF), and an 8-mer peptide fragment of urokinase (uPA).

9. The method of claim 1 , wherein the drug is dexamethasone.

10. The method of claim 1 , wherein the drug is a nucleic acid.

11. The method of claim 1 , wherein the intraocular disease comprises glaucoma, age-related macular degeneration (ARMD), choroidal neovascularization (CNV), or uveitis.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 27, 2015
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035501/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: FREEMAN, WILLIAM; SAILOR, MICHAEL J.; CHENG, LINGYUN; CUNIN, FREDERIQUE; ANGLIN, EMILY; LI, YANG YANG
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034520/0705 →
CONFIRMATORY LICENSE Recorded Apr 12, 2013
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030205/0174 →
Continuity (3)
Continuation 11665557
Provisional Application 60623409 · Oct 29, 2004
Related Publication 20130224302A1 · Aug 29, 2013